PharmaCorp Rx Statistics
Total Valuation
PharmaCorp Rx has a market cap or net worth of CAD 56.30 million. The enterprise value is 47.85 million.
| Market Cap | 56.30M |
| Enterprise Value | 47.85M |
Important Dates
The next estimated earnings date is Friday, November 7, 2025.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PharmaCorp Rx has 117.30 million shares outstanding. The number of shares has increased by 20.45% in one year.
| Current Share Class | 117.30M |
| Shares Outstanding | 117.30M |
| Shares Change (YoY) | +20.45% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 13.35% |
| Owned by Institutions (%) | n/a |
| Float | 101.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.05 |
| PB Ratio | 1.85 |
| P/TBV Ratio | 4.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 135.87 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -134.12 |
| EV / Sales | 3.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -27.64 |
Financial Position
The company has a current ratio of 5.58, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.58 |
| Quick Ratio | 4.77 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.51 |
| Interest Coverage | -23.35 |
Financial Efficiency
Return on equity (ROE) is -1.46% and return on invested capital (ROIC) is -1.96%.
| Return on Equity (ROE) | -1.46% |
| Return on Assets (ROA) | -1.80% |
| Return on Invested Capital (ROIC) | -1.96% |
| Return on Capital Employed (ROCE) | -2.59% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.47 |
| Inventory Turnover | 9.67 |
Taxes
In the past 12 months, PharmaCorp Rx has paid 159,485 in taxes.
| Income Tax | 159,485 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.43% in the last 52 weeks. The beta is -5.09, so PharmaCorp Rx's price volatility has been lower than the market average.
| Beta (5Y) | -5.09 |
| 52-Week Price Change | -30.43% |
| 50-Day Moving Average | 0.48 |
| 200-Day Moving Average | 0.49 |
| Relative Strength Index (RSI) | 50.54 |
| Average Volume (20 Days) | 63,106 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaCorp Rx had revenue of CAD 13.91 million and -356,770 in losses. Loss per share was -0.00.
| Revenue | 13.91M |
| Gross Profit | 5.46M |
| Operating Income | -859,772 |
| Pretax Income | -226,331 |
| Net Income | -356,770 |
| EBITDA | -308,997 |
| EBIT | -859,772 |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 9.56 million in cash and 878,899 in debt, giving a net cash position of 8.68 million or 0.07 per share.
| Cash & Cash Equivalents | 9.56M |
| Total Debt | 878,899 |
| Net Cash | 8.68M |
| Net Cash Per Share | 0.07 |
| Equity (Book Value) | 30.43M |
| Book Value Per Share | 0.26 |
| Working Capital | 9.81M |
Cash Flow
In the last 12 months, operating cash flow was 414,371 and capital expenditures -2.15 million, giving a free cash flow of -1.73 million.
| Operating Cash Flow | 414,371 |
| Capital Expenditures | -2.15M |
| Free Cash Flow | -1.73M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 39.25%, with operating and profit margins of -6.18% and -2.57%.
| Gross Margin | 39.25% |
| Operating Margin | -6.18% |
| Pretax Margin | -1.63% |
| Profit Margin | -2.57% |
| EBITDA Margin | -2.22% |
| EBIT Margin | -6.18% |
| FCF Margin | n/a |
Dividends & Yields
PharmaCorp Rx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.45% |
| Shareholder Yield | -20.45% |
| Earnings Yield | -0.63% |
| FCF Yield | -3.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PharmaCorp Rx has an Altman Z-Score of 7.97 and a Piotroski F-Score of 5.
| Altman Z-Score | 7.97 |
| Piotroski F-Score | 5 |